Vigil_Logo_TM (002).png
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
June 27, 2024 02:00 ET | Vigil Neuroscience, Inc.
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2...
Vigil_Logo_TM (002).png
Vigil Neuroscience to Present in Upcoming June Investor Conferences
May 30, 2024 07:05 ET | Vigil Neuroscience, Inc.
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
Vigil_Logo_TM (002).png
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
May 08, 2024 07:40 ET | Vigil Neuroscience, Inc.
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
Vigil_Logo_TM (002).png
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024 16:05 ET | Vigil Neuroscience, Inc.
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer’s disease ongoing;...
Vigil_Logo_TM (002).png
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
April 17, 2024 16:05 ET | Vigil Neuroscience, Inc.
- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology - - Positive interim IGNITE Phase 2 data demonstrating...
Vigil_Logo_TM (002).png
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 26, 2024 07:05 ET | Vigil Neuroscience, Inc.
– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment for IGNITE trial completed with 20 patients...
Vigil_Logo_TM (002).png
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
March 20, 2024 07:05 ET | Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil_Logo_TM (002).png
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
March 13, 2024 07:05 ET | Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil_Logo_TM (002).png
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
March 12, 2024 07:05 ET | Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil_Logo_TM (002).png
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
March 06, 2024 16:25 ET | Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...